[go: up one dir, main page]

WO2008146774A1 - テトラヒドロイソキノリン-1-オン誘導体またはその塩 - Google Patents

テトラヒドロイソキノリン-1-オン誘導体またはその塩 Download PDF

Info

Publication number
WO2008146774A1
WO2008146774A1 PCT/JP2008/059621 JP2008059621W WO2008146774A1 WO 2008146774 A1 WO2008146774 A1 WO 2008146774A1 JP 2008059621 W JP2008059621 W JP 2008059621W WO 2008146774 A1 WO2008146774 A1 WO 2008146774A1
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydroisoquinolin
derivative
receptor
found
ibs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/059621
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Hisamichi
Itsuro Shimada
Tsukasa Ishihara
Tomofumi Takuwa
Takafumi Shimizu
Noriko Ishikawa
Kyoichi Maeno
Norio Seki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40075016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008146774(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to RU2009148507/04A priority Critical patent/RU2479578C2/ru
Priority to AU2008255815A priority patent/AU2008255815B2/en
Priority to KR1020157019531A priority patent/KR101682638B1/ko
Priority to MX2009012779A priority patent/MX2009012779A/es
Priority to HRP20151336TT priority patent/HRP20151336T1/hr
Priority to SI200831545T priority patent/SI2149561T1/sl
Priority to ES08764654.3T priority patent/ES2558677T3/es
Priority to CN2008800139534A priority patent/CN101668747B/zh
Priority to PL08764654T priority patent/PL2149561T3/pl
Priority to DK08764654.3T priority patent/DK2149561T3/en
Priority to KR1020167033484A priority patent/KR101830566B1/ko
Priority to US12/600,894 priority patent/US8486970B2/en
Priority to JP2009516311A priority patent/JP5336359B2/ja
Priority to BRPI0812359-4A2A priority patent/BRPI0812359A2/pt
Priority to CA2688326A priority patent/CA2688326C/en
Priority to RS20150826A priority patent/RS54429B1/sr
Priority to EP08764654.3A priority patent/EP2149561B1/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of WO2008146774A1 publication Critical patent/WO2008146774A1/ja
Priority to ZA2009/08220A priority patent/ZA200908220B/en
Priority to IL202301A priority patent/IL202301A/en
Anticipated expiration legal-status Critical
Priority to US13/942,158 priority patent/US9150541B2/en
Priority to US14/836,228 priority patent/US9526719B2/en
Priority to US15/350,427 priority patent/US10016410B2/en
Priority to US16/027,988 priority patent/US10532048B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

【課題】医薬、殊に過敏性腸症候群（ＩＢＳ）治療剤として用いることのできる化合物の提供。 【解決手段】4位にアミド基を有することを特徴とするテトラヒドロイソキノリン-1-オン誘導体またはその製薬学的に許容される塩が、優れたボンベシン２(ＢＢ２)受容体拮抗作用を有することを見出した。また、これらのテトラヒドロイソキノリン-1-オン誘導体は便通異常に対して優れた有効性を示すことを見出した。以上のことから、本発明のテトラヒドロイソキノリン-1-オン誘導体はＢＢ２受容体の関与する疾患、殊にＩＢＳ治療薬として有用である。
PCT/JP2008/059621 2007-05-28 2008-05-26 テトラヒドロイソキノリン-1-オン誘導体またはその塩 Ceased WO2008146774A1 (ja)

Priority Applications (23)

Application Number Priority Date Filing Date Title
AU2008255815A AU2008255815B2 (en) 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof
JP2009516311A JP5336359B2 (ja) 2007-05-28 2008-05-26 テトラヒドロイソキノリン−１−オン誘導体またはその塩
KR1020157019531A KR101682638B1 (ko) 2007-05-28 2008-05-26 테트라히드로이소퀴놀린-1-온 유도체 또는 그의 염
MX2009012779A MX2009012779A (es) 2007-05-28 2008-05-26 Derivado de tetrahidroisoquinolin-1-ona o sal de el.
HRP20151336TT HRP20151336T1 (hr) 2007-05-28 2008-05-26 Tetrahidroizokinolin-1-on derivat ili njegova sol
SI200831545T SI2149561T1 (sl) 2007-05-28 2008-05-26 Derivat tetrahidroizokinolin-1-on ali njegova sol
ES08764654.3T ES2558677T3 (es) 2007-05-28 2008-05-26 Derivado de tetrahidroisoquinolin-1-ona o sal del mismo
CN2008800139534A CN101668747B (zh) 2007-05-28 2008-05-26 四氢异喹啉-1-酮衍生物或其盐
PL08764654T PL2149561T3 (pl) 2007-05-28 2008-05-26 Pochodna tetrahydroizochinolin-1-onu lub jej sól
DK08764654.3T DK2149561T3 (en) 2007-05-28 2008-05-26 Tetrahydroisoquinoline-1-one derivative or salt thereof
KR1020167033484A KR101830566B1 (ko) 2007-05-28 2008-05-26 테트라히드로이소퀴놀린-1-온 유도체 또는 그의 염
CA2688326A CA2688326C (en) 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof
BRPI0812359-4A2A BRPI0812359A2 (pt) 2007-05-28 2008-05-26 Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo
RU2009148507/04A RU2479578C2 (ru) 2007-05-28 2008-05-26 Производное тетрагидроизохинолин-1-она или его фармацевтически приемлемая соль, полезные в качестве антагониста вв2
US12/600,894 US8486970B2 (en) 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof
RS20150826A RS54429B1 (sr) 2007-05-28 2008-05-26 Derivat tetrahidroizokvinolin-1-ona ili njegova so
EP08764654.3A EP2149561B1 (en) 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof
ZA2009/08220A ZA200908220B (en) 2007-05-28 2009-11-20 Tetrahydroisoquinolin-1-one derivative or salt thereof
IL202301A IL202301A (en) 2007-05-28 2009-11-24 A tetrahydroisoquinoline-1-on or salt derivative
US13/942,158 US9150541B2 (en) 2007-05-28 2013-07-15 Tetrahydroisoquinolin-1-one derivative or salt thereof
US14/836,228 US9526719B2 (en) 2007-05-28 2015-08-26 Tetrahydroisoquinolin-1-one derivative or salt thereof
US15/350,427 US10016410B2 (en) 2007-05-28 2016-11-14 Tetrahydroisoquinolin-1-one derivative or salt thereof
US16/027,988 US10532048B2 (en) 2007-05-28 2018-07-05 Tetrahydroisoquinolin-1-one derivative or salt thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007140097 2007-05-28
JP2007-140097 2007-05-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/600,894 A-371-Of-International US8486970B2 (en) 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof
US13/942,158 Division US9150541B2 (en) 2007-05-28 2013-07-15 Tetrahydroisoquinolin-1-one derivative or salt thereof

Publications (1)

Publication Number Publication Date
WO2008146774A1 true WO2008146774A1 (ja) 2008-12-04

Family

ID=40075016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/059621 Ceased WO2008146774A1 (ja) 2007-05-28 2008-05-26 テトラヒドロイソキノリン-1-オン誘導体またはその塩

Country Status (23)

Country Link
US (5) US8486970B2 (ja)
EP (1) EP2149561B1 (ja)
JP (1) JP5336359B2 (ja)
KR (3) KR101830566B1 (ja)
CN (1) CN101668747B (ja)
AU (1) AU2008255815B2 (ja)
BR (1) BRPI0812359A2 (ja)
CA (1) CA2688326C (ja)
CY (1) CY1117004T1 (ja)
DK (1) DK2149561T3 (ja)
ES (1) ES2558677T3 (ja)
HR (1) HRP20151336T1 (ja)
HU (1) HUE026316T2 (ja)
IL (1) IL202301A (ja)
MX (1) MX2009012779A (ja)
PL (1) PL2149561T3 (ja)
PT (1) PT2149561E (ja)
RS (1) RS54429B1 (ja)
RU (1) RU2479578C2 (ja)
SI (1) SI2149561T1 (ja)
TW (1) TWI425945B (ja)
WO (1) WO2008146774A1 (ja)
ZA (1) ZA200908220B (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
CN110563687A (zh) * 2019-07-23 2019-12-13 上海合全医药有限公司 一种4-(氨基甲基)色烷-3-醇的制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016053621A1 (en) * 2014-09-16 2016-04-07 Sri International Affinity reagent and catalyst discovery though fiber-optic array scanning technology
WO2017140728A1 (en) * 2016-02-15 2017-08-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Taf1 inhibitors for the therapy of cancer
WO2018018035A1 (en) * 2016-07-22 2018-01-25 Virginia Commonwealth University Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-hmf) and its derivatives
EP3768266A4 (en) * 2018-03-20 2021-12-22 Merck Sharp & Dohme Corp. OXO-TETRAHYDRO-ISOCHINOLINE-CARBOXYLIC ACIDS AS STING INHIBITORS
BR112023021344A2 (pt) 2021-04-15 2023-12-19 Pags Co Ltd Derivados de isoquinolinas para uso como agentes antivirais e antitumorais
EP4074314A1 (en) * 2021-04-15 2022-10-19 Valdospan GmbH Isoquinoline derivatives for use as antiviral and antitumour agents
CN113603625B (zh) * 2021-08-12 2023-03-10 南京卓康医药科技有限公司 一种酮咯酸中间体的合成方法
KR20250073675A (ko) 2022-10-17 2025-05-27 알디피 파마 아게 단백질 분해제, e7 분해제, 항바이러스제, 종양 치료제 및 면역 억제제로서의 이소퀴놀린 유도체

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029221A1 (de) 2001-09-24 2003-04-10 Bayer Healthcare Ag Tetrahydroisochinoline, ihre herstellung und verwendung als schmerzmittel
WO2004004727A1 (en) 2002-07-03 2004-01-15 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
WO2006097323A1 (en) 2005-03-18 2006-09-21 Lutz Weber TETRAHYDRO-ISOQUINOLIN-l-ONES FOR THE TREATMENT OF CANCER
WO2006115135A1 (ja) 2005-04-21 2006-11-02 Astellas Pharma Inc. 過敏性腸症候群治療剤
WO2007105989A2 (en) * 2006-03-14 2007-09-20 Ivashchenko, Andrey Alexandrovich 1-oxo-3-(1h-indole)-3-il-1,2,3,4-tetrahydroisoxynolines, methods for the production thereof, combinatoric library and focused library
WO2007133108A1 (en) * 2006-05-12 2007-11-22 Chemdiv, Ink. Pharmaceutical composition, method for the production and the use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
EP1155001A4 (en) 1999-02-22 2003-05-28 Lion Bioscience Ag ISOQUINOLEIN DERIVATIVES AND COMBINATORIAL ISOQUINOLEIN BANKS
US6787534B2 (en) * 1999-12-28 2004-09-07 Eisai Co., Ltd. Sulfonamide-containing heterocyclic compounds
ATE292625T1 (de) * 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
AR035513A1 (es) * 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
WO2004080968A1 (en) * 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
US7056930B2 (en) * 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
NZ593444A (en) * 2003-10-01 2012-12-21 Adolor Corp 4-[(2-N,N-diethylaminocarbonyl)pyrid-5-yl]-spiro[1,2-dihydronaphthalene-2,4'-piperidine] and methods of its use
EP1630159A1 (en) * 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
EP1838296B1 (en) 2004-10-20 2012-08-08 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US8367699B2 (en) * 2006-09-15 2013-02-05 Nexuspharma, Inc. Tetrahydro-isoquinolines
CN101686952A (zh) * 2007-03-12 2010-03-31 Vm生物医药公司 新型钙离子通道调节剂
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
PT2149560E (pt) * 2007-05-22 2015-07-13 Astellas Pharma Inc Composto de tetra-hidroisoquinolina substituído na posição 1
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029221A1 (de) 2001-09-24 2003-04-10 Bayer Healthcare Ag Tetrahydroisochinoline, ihre herstellung und verwendung als schmerzmittel
JP2005510475A (ja) * 2001-09-24 2005-04-21 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロイソキノリン、それらの製造方法、および麻酔薬としてのそれらの使用
WO2004004727A1 (en) 2002-07-03 2004-01-15 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
WO2006097323A1 (en) 2005-03-18 2006-09-21 Lutz Weber TETRAHYDRO-ISOQUINOLIN-l-ONES FOR THE TREATMENT OF CANCER
WO2006115135A1 (ja) 2005-04-21 2006-11-02 Astellas Pharma Inc. 過敏性腸症候群治療剤
WO2007105989A2 (en) * 2006-03-14 2007-09-20 Ivashchenko, Andrey Alexandrovich 1-oxo-3-(1h-indole)-3-il-1,2,3,4-tetrahydroisoxynolines, methods for the production thereof, combinatoric library and focused library
WO2007133108A1 (en) * 2006-05-12 2007-11-22 Chemdiv, Ink. Pharmaceutical composition, method for the production and the use thereof

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Drug Design", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, article "Pharmaceutical Research and Development", pages: 163 - 198
"Protective Groups in Organic Synthesis", 1999
AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 98, 2003, pages 750 - 758
ANNALS OF THE NEW YORK ACADEMY OF SCIENCE, vol. 921, 2000, pages 420 - 424
BRITISH JOURNAL OF CANCER, vol. 83, 2000, pages 906 - 913
CANCER, vol. 83, 1998, pages 1335 - 1343
CANCER, vol. 88, 2000, pages 1384 - 1392
GASTROENTEROLOGY, vol. 100, 1991, pages 980 - 985
GUT, vol. 42, 1998, pages 845 - 849
LIFE SCIENCES, vol. 70, 2002, pages 2953 - 2966
NEUROGASTROENTEROLOGY AND MOTILITY, vol. 9, 1997, pages 265 - 270
PROG. MED., vol. 5, 1985, pages 2157 - 2161
See also references of EP2149561A4
THE JOURNAL OF NEUROSCIENCE, vol. 18, 1998, pages 4758 - 4766

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
CN110563687A (zh) * 2019-07-23 2019-12-13 上海合全医药有限公司 一种4-(氨基甲基)色烷-3-醇的制备方法
CN110563687B (zh) * 2019-07-23 2022-09-30 上海合全医药有限公司 一种4-(氨基甲基)色烷-3-醇的制备方法

Also Published As

Publication number Publication date
TWI425945B (zh) 2014-02-11
SI2149561T1 (sl) 2016-02-29
KR101830566B1 (ko) 2018-02-20
US10016410B2 (en) 2018-07-10
PT2149561E (pt) 2016-01-07
RU2009148507A (ru) 2011-07-10
CA2688326A1 (en) 2008-12-04
TW200911251A (en) 2009-03-16
HRP20151336T1 (hr) 2016-01-15
ZA200908220B (en) 2011-02-23
AU2008255815A1 (en) 2008-12-04
RS54429B1 (sr) 2016-04-28
JP5336359B2 (ja) 2013-11-06
JPWO2008146774A1 (ja) 2010-08-19
IL202301A0 (en) 2010-06-30
CA2688326C (en) 2016-07-05
US9526719B2 (en) 2016-12-27
US20140058100A1 (en) 2014-02-27
CN101668747B (zh) 2012-02-01
US20170189390A1 (en) 2017-07-06
US10532048B2 (en) 2020-01-14
US8486970B2 (en) 2013-07-16
HUE026316T2 (en) 2016-06-28
AU2008255815B2 (en) 2012-02-02
RU2479578C2 (ru) 2013-04-20
MX2009012779A (es) 2010-02-17
CN101668747A (zh) 2010-03-10
EP2149561A4 (en) 2011-09-07
US20100227866A1 (en) 2010-09-09
US20190000832A1 (en) 2019-01-03
EP2149561A1 (en) 2010-02-03
BRPI0812359A2 (pt) 2015-01-27
CY1117004T1 (el) 2017-04-05
KR101682638B1 (ko) 2016-12-05
KR20150090262A (ko) 2015-08-05
KR20100020982A (ko) 2010-02-23
EP2149561B1 (en) 2015-09-09
PL2149561T3 (pl) 2016-05-31
US20150359787A1 (en) 2015-12-17
ES2558677T3 (es) 2016-02-08
KR101580298B1 (ko) 2016-01-08
IL202301A (en) 2017-07-31
DK2149561T3 (en) 2015-12-21
KR20160139067A (ko) 2016-12-06
US9150541B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
WO2008146774A1 (ja) テトラヒドロイソキノリン-1-オン誘導体またはその塩
IL192948A0 (en) Novel pyridine derivatives
MY154909A (en) Novel thiophene derivatives
WO2007150025A3 (en) Purinone derivatives as hm74a agonists
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
MY145074A (en) Thiazolidin-4-one derivatives
HK1259250A1 (zh) 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
WO2007135527A3 (en) Benzimidazolyl compounds
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
WO2009042114A3 (en) Phenazine derivatives and uses thereof
MX2009004662A (es) Compuestos de pirazolina como antagonistas receptores de mineralocorticoides.
MX2009000001A (es) Compuestos terapeuticos.
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
TW200942524A (en) Novel aminomethyl benzene derivatives
DK2146991T3 (da) Triazolopyridin-carboxamid-derivater, fremstilling af samme samt terapeutisk anvendelse deraf
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2009038412A3 (en) Beta-secretase inhibiting compounds
IT1400989B1 (it) Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880013953.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764654

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009516311

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008255815

Country of ref document: AU

Ref document number: 12009502202

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 12600894

Country of ref document: US

Ref document number: 2008764654

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2688326

Country of ref document: CA

Ref document number: MX/A/2009/012779

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 6958/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008255815

Country of ref document: AU

Date of ref document: 20080526

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20097027024

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009148507

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0812359

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091130

WWE Wipo information: entry into national phase

Ref document number: P-2015/0826

Country of ref document: RS